Speaker Profile

PHARM.D., PhD, Professor of Neurology & Epidemiology, Director Program in Translational PGx and Associate Director, Personalized Medicine Institute, UAB

Dr. Limdi started her career as a pharmacist after graduating from Samford University with a PharmD (1994). Her observations on variability of drug response fueled her interests in understanding genetic underpinnings of drug response. She continued her training obtaining her MSPH (2005) and PhD in Epidemiology (2007). As a clinical pharmacist and chronic disease epidemiologist with 20 years of experience, she brings her breath of expertise in clinical pharmacy, chronic disease epidemiology, and pharmacogenomics to lead research and implementation of genomics in clinical practice. Her efforts to recruit and engage African Americans (AA) and medically underserved patients has been vital to her contributions to understanding racial differences in drug response, identifying race-specific variants, reporting on the differential impact of gene variants and comorbidities by race. Through her work, Dr. Limdi has collaborated extensively with national/ international consortia including: the Pharmacogenomics Research Network, the Pharmacogenomics Knowledge Base, the Clinical Pharmacogenetics Implementation Committee, the Implementation of Genomics In pracTicE, the Alabama Genomic health Initiative, the Personalized Medicine Coalition, the Standardizing Laboratory Practices in Pharmacogenomics, and the Electronic Medical Records and Genomics.

 Session Abstract – PMWC 2022 Silicon Valley

Track Chairs:
Philip Empey, UPitt
Mary V. Relling, St. Jude Children’s Research Hospital
Stuart Scott, Stanford

Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.

  • Keynote: The Future Of PGx
    - Julie Johnson, University of Florida
  • PGx Research and Discovery
    - Estenab Burchard, UCSF
    - William Evans, St. Jude's
    - Jose Estabil, Cipherome
    - James Coons, UPMC
    - Todd Skaar, Indiana University
  • Innovative Industry Solutions
    - Jeffrey A. Shaman, Coriell Life Sciences
    - Akwasi Asabere, Helix
    - Gillian Bell, Genome Medical
    - Cindy Kosinski, 23andme
  • Key Resources for PGx
    - Kelly E. Caudle, St. Jude Children’s Research Hospital
    - Michelle Whirl-Carillo, Stanford
  • Clinical Laboratory PGx Considerations
    - Ulrich Broeckel, MCW
    - Stuart Scott, Stanford
    - Victoria Pratt, Indiana University
  • Lessons from Frontline PGx Clinical Services
    - Mark H. Dunnenberger, Northshore University HealthSystem
    - Lucas Berenbrok, UPitt
    - Sony Tuteja, UPenn
    - Burns Blaxall, The Christ Hospital Health Network
  • Translational PGx Implementation Programs
    - Philip Empey, UPitt
    - Julie A. Johnson, Uinversity of Florida
    - Mary V. Relling, St. Jude Children’s Research Hospital
    - Laura Ramsey, Cincinnati Children's Hospital
    - Nita A. Limdi, UAB